Distribution Of Industrial Hemp "Collar" Letter Of Concern, Germany Exhibition Health Said No Investment In Hemp Investment

In the field of industrial cannabis, after the introduction of enterprises such as Kang Bei and long Jin pharmaceutical, it has attracted the attention of regulators.

In March 12th, the Shenzhen Stock Exchange issued a letter of concern about the development of Germany's health.

In March 16th, the German exhibition responded to the health announcement. It said there was no other capital and business dealings between the Han group and its associated parties, and there was no detailed investigation of hemp investment.

Germany exhibition health layout industrial hemp

In March 12th, due to the many problems involved in the cooperation agreement between the Han group and the hemp health industry, the German leader was led to the attention letter of the Shenzhen Stock Exchange, and asked for the health of the German export company to explain the existence of funds and business and the rationality of the 400 million Yuan sincerity.

In March 16th, the German exhibition Health said in reply to the letter of concern of the Shenzhen Stock Exchange, in addition to the relevant pactions, there was no other capital and business dealings with Han Zhong Group and its associated parties. Nor did Han Zhong Group found that the group was the controlling shareholder of the company and its controlling shareholder, holding 5% of shareholders.

In 2018, the revenue and net profit of Germany exhibition were 146 million yuan and 87 million 385 thousand and 400 yuan respectively.

The letter from the Shenzhen Stock Exchange also asked for the health of Germany to carry out due diligence, audit or asset assessment on the investment of hemp.

In this regard, the German development Health said that the former member of the framework agreement had made an internal due diligence investigation. However, in view of the fact that only a preliminary consensus has been reached, the formal trading scheme will be further negotiated between the two sides of the paction.

At the same time, he said that during the exclusive partnership period, the paction will be fully promoted and the securities service agencies should be hired as soon as possible to audit or evaluate the underlying assets.

It is reported that Germany exhibition health has paid 70 million yuan and 30 million yuan to the Han people group in March 8th and March 11th respectively, and the remaining sincerity fund will continue to perform in accordance with the framework agreement.

Opening up the field of Biopharmaceutics

In recent years, the process of legalization of cannabis in overseas countries has accelerated. Currently, medical marijuana has been legalized in dozens of countries around the world.

In 2016 and 2017, the British medicines and health products administration and WHO acknowledged the medicinal value of two CBD.

In 2018, Epidiolex, a CBD extracted from plants, was approved for sale in the United States for the treatment of epilepsy related diseases.

According to a study released by Pacific Securities in March 2019, the value of the global hemp market is about 12 billion 900 million dollars in 2018, and is expected to reach US $23 billion in 2022.

The value of global CBD industry will reach US $5 billion 700 million in 2019 and US $18 billion 100 million by 2021.

According to the research report released by Guo Hai securities in January 30, 2019, China accounted for 25% of the total output of hemp and hemp in the world, and the output of hemp in China was 77 thousand tons in 2016. It is estimated that the output of hemp in China will reach 103 thousand tons in 2021.

By the end of 2017, the market size of China's Hemp two phenol industry has reached 448 million yuan. It is expected to rise to 547 million yuan in 2018 and 1 billion 800 million yuan in 2024, with a compound growth rate of 21.96%.

It is also based on the prospect of industrial hemp prospects. In the evening of March 8th, the German Health Exhibition issued a strategic cooperation framework agreement with Han Zhong Group and hemp investment to carry out deep cooperation on the health industry of cannabis and establish a comprehensive strategic partnership.

The three party signed a cooperation framework agreement. Han Zhong Group mortgaged its 25% stake in hemp investment to Germany exhibition health, and Germany exhibition health. After the Han nationality group completed the equity pledge procedure of Han Ma investment, it paid a total of 400 million yuan to the Han Zhong Group.

The three party agrees that the way of cooperation to achieve the purpose of strategic cooperation includes, but is not limited to, Germany exhibition health, equity purchase, investment increase, participation in the establishment of new companies and investment funds, the pfer of patent rights or know-how, etc.

Hemp investment is currently the only legal group in China that is based on the whole industrial chain layout of industrial hemp and bio pharmaceutical as the direction, and has made remarkable achievements in setting industry standards and industry norms.

The company has signed a framework agreement with Han Zhong Group and hemp investment to form a strategic partnership, which is conducive to the layout of the industrial hemp industry chain, the development of the biopharmaceutical field, and the enrichment of the company's product pipeline.